Medical research is constantly evolving, with discoveries and advances emerging every day. Biological and pharmaceutical companies are experiencing a surge in workload due to the rapid pace of innovation, so CROs assist the companies with streamlining and systematizing the research process. Medical device CROs provide research services contractually to medical device industries. Technology advancements have provided CROs with opportunities to further improve and evolve their services, such as technology-enabled patient recruitment and management, decentralized and remote trials, wearable technology, and biosimulation.
Medical device contract research organizations are projected to generate $14.01 bn in revenue by 2030, representing an 8.8 percent CAGR from 2023 to 2030. The increased demand for advanced devices for screening and monitoring surgical procedures is expected to result from this market growth. The industry is driven by the benefits of time-saving, cost-efficiency, and expertise, which promotes the production of devices faster. Contract research organizations will have access to the latest technological resources, such as hardware, software, and internet-based applications, to ensure that the process is as efficient as possible while maintaining the highest level of quality.
This edition of the Pharma Tech Outlook brings forth the most significant developments in medical device CRO providing services to medical device manufacturers to assist them with clinical trial design, execution, and data analysis.
It features thought leadership articles from Ozgur Akbulut, Director - Global Divestments and Contract Manufacturing Lead at Takeda [NYSE:TAK] James Riddle, MCSE, CIP, CPIA, CRQM, Vice President, Research Services & Strategic Consulting at Advarra. Ozgur Akbulut discusses how pharma companies seek efficient operational excellence and continuous improvement. James Riddle talks about how immunotherapy and gene editing may cure previously incurable conditions. It also features an article from Stewart Campbell, VP & General Manager at West Pharmaceutical & Li Chen, VP & General Manager at West Pharmaceutical, who sheds light on the shifting trends in oncology drug development that pose a challenge for manufacturing companies.
In this edition of Pharma Tech Outlook, we also bring you the story of some of the medical device CROs companies that cater to delivering disruptive technologies and tasks related to developing and commercializing their products. One of them is NAMSA, one of the world’s leading MedTech Contract Research Organizations (CRO), offering global end-to-end development services.
In this edition featuring the medical device CROs 2023, we hope you find the right partner for your organization’s performance and needs.


-1.jpg)






